Opioid Response in an Individual with Altered CYP2D6 Activity: Implications of a Pharmacogenomics Case

Abstract

The benefits of opioid use in older adults to manage chronic non-cancer pain must outweigh the risks as these individuals are more susceptible to the side effects and drug interactions associated with opioids. Pharmacogenomic testing supports clinicians to select an appropriate opioid therapy while minimizing these risks.